mass lesion with immunosuppressive therapy. 41, 42 Very low to low Other considerations Recommendation: In patients with GPA/MPA, we conditionally recommend against dosing immunosuppressive therapy based on ANCA titer results alone. Very low Recommendation: For patients with GPA who are receiving rituximab or cyclophosphamide, we conditionally recommend prophylaxis to prevent Pneumocystis jirovecii pneumonia. Low Recommendation: For patients with GPA/MPA in remission and stage 5 chronic kidney